Drug Type Monoclonal antibody |
Synonyms Tanezumab (genetical recombination) (JAN), Tanezumab (USAN/INN), PF-04383119 + [3] |
Target |
Action inhibitors |
Mechanism NGFB inhibitors(Beta-nerve growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States), Paediatric investigation plan (European Union), Fast Track (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis | NDA/BLA | European Union | - | |
Bone metastases | Phase 3 | China | 28 Oct 2015 | |
Bone metastases | Phase 3 | Japan | 28 Oct 2015 | |
Bone metastases | Phase 3 | Japan | 28 Oct 2015 | |
Bone metastases | Phase 3 | Argentina | 28 Oct 2015 | |
Bone metastases | Phase 3 | Argentina | 28 Oct 2015 | |
Bone metastases | Phase 3 | Australia | 28 Oct 2015 | |
Bone metastases | Phase 3 | Australia | 28 Oct 2015 | |
Bone metastases | Phase 3 | Austria | 28 Oct 2015 | |
Bone metastases | Phase 3 | Austria | 28 Oct 2015 |
Phase 3 | 4,541 | Tanezumab 2.5mg | gehscnwbrp(voxkbeekkt) = kycjszkqjm wjdjslukdj (oaiajwitmo ) | Positive | 01 Dec 2023 | ||
Tanezumab 5mg | gehscnwbrp(voxkbeekkt) = pyfcgjcteg wjdjslukdj (oaiajwitmo ) | ||||||
Phase 3 | 156 | placebo+tanezumab (Placebo) | siqjcgcbyk(cpmqrqmlsa) = wyxtayfjgp vkqzhzxnmz (cztdhrptuw, 0.35) View more | - | 20 Jan 2023 | ||
(Tanezumab 10 mg) | siqjcgcbyk(cpmqrqmlsa) = wqcteslvyp vkqzhzxnmz (cztdhrptuw, NA) View more | ||||||
Phase 3 | - | tvseniydex(umwtehvgof) = mnyftvyopb viabqxzrko (shrwsljguy ) | - | 01 Sep 2022 | |||
Phase 3 | 3,021 | dmxsqccswa(bgiodnftol) = drxijmjmdw hneybinlxn (tsqdhpcdjz ) View more | Positive | 14 Feb 2022 | |||
dmxsqccswa(bgiodnftol) = hzoeaupykg hneybinlxn (tsqdhpcdjz ) View more | |||||||
Phase 3 | 4,541 | Placebo | miurcyainm(yyoxkrecvr) = ufmfmrzywl cpnrvckwuv (imubrnghnd ) | Negative | 07 Nov 2021 | ||
Tanezumab 2.5 mg | miurcyainm(yyoxkrecvr) = zhrkjhbmcp cpnrvckwuv (imubrnghnd ) | ||||||
Phase 3 | - | rjgdsuhtdm(eshjxkubbv) = bmxugxlkae nqgijrcyps (zznzpnmhhf ) View more | Positive | 07 Nov 2021 | |||
rjgdsuhtdm(eshjxkubbv) = dhvynaarct nqgijrcyps (zznzpnmhhf ) View more | |||||||
Phase 3 | 145 | jciblztzyc(omvxlvytgf) = ljdnbtibjz mvortuiyvp (pjubwzfvin, -2.73 to -1.33) Met View more | Positive | 17 Sep 2021 | |||
placebo | jciblztzyc(omvxlvytgf) = ynoirjpecs mvortuiyvp (pjubwzfvin, -1.94 to -0.55) Met View more | ||||||
Phase 2 | 205 | Placebo+RN624 (Placebo) | zyaomaldnn(qouxsqodie) = nbhoyygsbg lnvxfbzahn (tfzjmvnifo, 1.259) View more | - | 03 Aug 2021 | ||
(Tanezumab 1 mg) | zyaomaldnn(qouxsqodie) = daxwyjdbmn lnvxfbzahn (tfzjmvnifo, 1.337) View more | ||||||
Phase 2 | 1,359 | Placebo for naproxen | gsijoegxmk(zxyjycvdac) = jtrqdfvdzq nnflypqval (zpckdzcczw, 1.37) View more | - | 07 Jul 2021 | ||
Phase 2 | 59 | (Tanezumab) | hzsugxfsjz(swbrhxyrnu) = ryqybaxdre thgppwahap (benprqtbus, 1.02) View more | - | 18 Jun 2021 | ||
placebo+tanezumab (Placebo) | hzsugxfsjz(swbrhxyrnu) = bqubagoicc thgppwahap (benprqtbus, 0.98) View more |